Pareto Bio is creating novel microbiome-based interventions to retrain the immune system to become tolerant against disease. Pareto Bio's lead therapy can induce specific Tregs that are decreased in food allergic patients, and has best-in-class potential to treat, cure and prevent various atopic conditions. The company is also investigating novel biomarkers, drug targets and microbiome-derived actives to scale its platform and portfolio.